Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

morningstar.com·Aug 28, 2026 · 13 g fa

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

endpoints.news·Aug 28, 2026 · 13 g fa

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

morningstar.com·Aug 29, 2026 · 13 g fa

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

medpagetoday.com·Aug 31, 2026 · 10 g fa

First-in-Class Drug Wins FDA Approval for Polycythemia Vera

benzinga.com·Aug 31, 2026 · 10 g fa

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)

fiercepharma.com·Aug 29, 2026 · 13 g fa

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

statnews.com·Aug 30, 2026 · 11 g fa

FDA approves Protagonist and Takeda’s drug for rare blood cancer

biopharmadive.com·Aug 31, 2026 · 11 g fa

FDA OKs Takeda, Protagonist drug for rare blood cancer

benzinga.com·Aug 31, 2026 · 10 g fa

FDA Clears First Targeted Dermatomyositis Treatment From Roivant - Roivant Sciences (NASDAQ:ROIV)

medpagetoday.com·Sep 4, 2026 · 6 g fa

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win